Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

H. Jack West, MD

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).
Printer Printing...